When encountering a prospect who pushes back, the best strategy is not to argue or prove them wrong. Instead, give them the space to find their own way into your solution. Trying to force their conversion only increases resistance; allowing them autonomy can turn them into your strongest advocates.

When a prospect immediately rejects your pitch, consider if your solution threatens their role. A billing director hearing about an 'outsourced' service isn't evaluating its benefit to the company; they are reacting to the personal threat of being replaced, making them a biased stakeholder.

The common "not interested" objection is a reflexive response, not a real reason. Instead of arguing, agree and offer multiple-choice reasons for their disinterest (e.g., problem isn't a priority, existing solution). This disarms them and surfaces the actual obstacle you need to address.

Getting a partnership deal done requires more than a good pitch; it requires an internal advocate. Leaders should leverage their network to identify and cultivate a champion inside the target company. This person is critical for navigating internal bureaucracy and pushing the deal over the goal line, as "there's a million ways for deals to die."

An investor's best career P&L winners are not immediate yeses. They often involve an initial pass by either the investor or the company. This shows that timing and building relationships over multiple rounds can be more crucial than a single early-stage decision, as a 'missed round' isn't a 'missed company'.

When seeking partnerships, biotechs should structure their narrative around three core questions pharma asks: What is the modality? How does the mechanism work? And most importantly, why is this the best differentiated approach to solve a specific clinical challenge and fit into the competitive landscape?

In large deals, internal 'enemies' often champion a competing solution. Top reps know the goal isn't to win these individuals over, which is often impossible. Instead, they focus on engaging them directly to neutralize their opposition, preventing them from actively derailing the deal.

Founders pitching pharma must determine if their solution is being 'pulled' by a stated R&D priority or 'pushed' by an enthusiastic innovation scout. A 'pull' signifies a fast-track deal process, while a 'push' could mean a multi-year educational journey before any deal is possible.

When investors say "no," don't just accept it. Reframe their decision as a potential mistake, comparing it to common investor errors like overlooking a great founder due to market concerns. This tactic, which turned two rejections into $12M, repositions you from supplicant to a confident peer and can reopen the conversation.